| __timestamp | Halozyme Therapeutics, Inc. | Ionis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 35942000 | 20140000 |
| Thursday, January 1, 2015 | 40028000 | 37173000 |
| Friday, January 1, 2016 | 45853000 | 48616000 |
| Sunday, January 1, 2017 | 53816000 | 108488000 |
| Monday, January 1, 2018 | 60804000 | 244622000 |
| Tuesday, January 1, 2019 | 77252000 | 287000000 |
| Wednesday, January 1, 2020 | 45736000 | 354000000 |
| Friday, January 1, 2021 | 50323000 | 186000000 |
| Saturday, January 1, 2022 | 143526000 | 151000000 |
| Sunday, January 1, 2023 | 149182000 | 232600000 |
| Monday, January 1, 2024 | 154335000 | 267474000 |
Cracking the code
In the competitive landscape of biotechnology, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Halozyme Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Ionis consistently outpaced Halozyme in SG&A spending, peaking in 2020 with a 75% higher expenditure than Halozyme. Notably, Halozyme's SG&A expenses surged by over 300% from 2014 to 2023, reflecting strategic investments in growth. Meanwhile, Ionis experienced a more volatile trend, with a significant spike in 2020, followed by a 34% decrease in 2021. These trends highlight the differing strategic priorities and operational scales of the two companies. As the biotech sector evolves, monitoring such financial metrics provides valuable insights into corporate strategies and market positioning.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc. or Halozyme Therapeutics, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ionis Pharmaceuticals, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Grifols, S.A.
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Verona Pharma plc
Halozyme Therapeutics, Inc. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or MannKind Corporation
Comparing SG&A Expenses: Ionis Pharmaceuticals, Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.